Targeting YAP in pancreatic ductal adenocarcinoma (PDAC) (Homo sapiens)
From WikiPathways
Description
"Targeting YAP for PDAC therapy. There are several strategies for targeting YAP in PDAC. Statin-mediated inhibition of HMG-CoA reductase in the mevalonate pathway reduces the geranylgeranylation and membrane localization of Rho GTPases, restricting YAP nuclear accumulation and thus its activity. Verteporfin and VGLL4-mimicking peptides disrupt the interaction between YAP and TEAD, inhibiting YAP-induced transcription. Metformin activates AMPK, which inhibits YAP both directly and by activating LATS kinases. BET inhibitors oppose the transcription of YAP-regulated genes. Neratinib increases the phosphorylation of LATS1 and YAP, causing YAP cytosolic accumulation and degradation." Based on Figure F5 in https://pubmed.ncbi.nlm.nih.gov/33408779/. Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC7778590__thnov11p1753g005.html.
Quality Tags
Ontology Terms
Pathway Ontology : signaling pathway
Cell Type : plant cell
Bibliography
- Mao W, Mai J, Peng H, Wan J, Sun T; ''YAP in pancreatic cancer: oncogenic role and therapeutic strategy.''; Theranostics, 2021 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Name ![]() | Type ![]() | Database reference ![]() | Comment ![]() |
---|---|---|---|
Atorvastatin | Metabolite | CHEBI:39548 (ChEBI) ![]() | |
CCN1 | GeneProduct | ENSG00000142871 (Ensembl) ![]() | |
CCN2 | GeneProduct | ENSG00000118523 (Ensembl) ![]() | |
Cell growth | |||
Cell proliferation | |||
Cell survival | |||
Fluvastatin | Metabolite | CHEBI:38561 (ChEBI) ![]() | |
HMG-CoA | Metabolite | CHEBI:15467 (ChEBI) ![]() | |
HMGCR | GeneProduct | ENSG00000113161 (Ensembl) ![]() | "HMG-CoA reductase" originally |
JQ1 | Metabolite | ||
LATS1 | GeneProduct | ENSG00000131023 (Ensembl) ![]() | |
LATS2 | GeneProduct | ENSG00000150457 (Ensembl) ![]() | |
Lovastatin | Metabolite | CHEBI:40303 (ChEBI) ![]() | |
MOB1A | GeneProduct | ENSG00000114978 (Ensembl) ![]() | |
Metformin | Metabolite | CHEBI:6801 (ChEBI) ![]() | |
Mevalonate pathway | Pathway | ||
Mevalonic acid | Metabolite | CHEBI:25351 (ChEBI) ![]() | |
Neratinib | Metabolite | CHEBI:61397 (ChEBI) ![]() | |
PRKAA1 | GeneProduct | ENSG00000132356 (Ensembl) ![]() | |
PRKAA2 | GeneProduct | ENSG00000162409 (Ensembl) ![]() | |
PRKAB1 | GeneProduct | ENSG00000111725 (Ensembl) ![]() | |
PRKAB2 | GeneProduct | ENSG00000131791 (Ensembl) ![]() | |
PRKAG1 | GeneProduct | ENSG00000181929 (Ensembl) ![]() | |
PRKAG2 | GeneProduct | ENSG00000106617 (Ensembl) ![]() | |
PRKAG3 | GeneProduct | ENSG00000115592 (Ensembl) ![]() | |
Pitavastatin | Metabolite | CHEBI:32020 (ChEBI) ![]() | |
Pravastatin | Metabolite | CHEBI:63618 (ChEBI) ![]() | |
RHOA | GeneProduct | ENSG00000067560 (Ensembl) ![]() | |
RHOB | GeneProduct | ENSG00000143878 (Ensembl) ![]() | |
RHOC | GeneProduct | ENSG00000155366 (Ensembl) ![]() | |
RHOD | GeneProduct | ENSG00000173156 (Ensembl) ![]() | |
RHO | GeneProduct | ENSG00000163914 (Ensembl) ![]() | |
Rosuvastatin | Metabolite | CHEBI:38545 (ChEBI) ![]() | |
SAV1 | GeneProduct | ENSG00000151748 (Ensembl) ![]() | |
STK3 | GeneProduct | ENSG00000104375 (Ensembl) ![]() | |
STK4 | GeneProduct | ENSG00000101109 (Ensembl) ![]() | |
Simvastatin | Metabolite | CHEBI:9150 (ChEBI) ![]() | |
TEAD1 | GeneProduct | ENSG00000187079 (Ensembl) ![]() | |
TEAD2 | GeneProduct | ENSG00000074219 (Ensembl) ![]() | |
TEAD3 | GeneProduct | ENSG00000007866 (Ensembl) ![]() | |
TEAD4 | GeneProduct | ENSG00000197905 (Ensembl) ![]() | |
VGLL4-mimicking peptides | Metabolite | ||
Verteporfin | Metabolite | CHEBI:32293 (ChEBI) ![]() | |
YAP1 | GeneProduct | ENSG00000137693 (Ensembl) ![]() |
Annotated Interactions
No annotated interactions